WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
CSPC will receive an upfront payment of $100 million from AstraZeneca
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Poor oral health (periodontal disease) impacts nearly 51% of Indians
India has taken the lead in recognising NAFLD as a major non-communicable disease
Quinidine Sulphate helps manage rare irregular heartbeat conditions
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Subscribe To Our Newsletter & Stay Updated
